Drug Trial Radar · NCT02367456
A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients
Last checked: Nov 19, 2026Latest source record: Jan 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
Apr 28, 2015
Primary completion
Jan 29, 2020
Study completion Mar 7, 2022
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Feb 20, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multi center open label Phase 1b study is designed to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of glasdegib (PF-04449913) when combined with azacitidine in patients with previously untreated Higher Risk Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML). This clinical study includes two components: (a) a safety lead in cohort (LIC) and (b) an expansion phase with an AML cohort and an MDS cohort.
Conditions
- Myelodysplastic Syndrome
- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
Interventions
PF-04449913 (Glasdegib)Drug
Daily dose of PF-04449913 100mg tablet in a continuous regimen of 28 day cycles
AzacitidineDrug
75mg/m2 on Days 1-7 (+/- 3 days for each dose) of a 28 day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Lead-in Cohort (LIC)Time frame: maximum of approximately 15 months
- Number of Participants With Serious Adverse Events (SAEs) in the LICTime frame: maximum of approximately 15 months
- Number of Participants With Laboratory Abnormalities in the LICTime frame: maximum of approximately 16 months
- Percentage of Participants Achieving Complete Remission (CR) in the AML and MDS CohortsTime frame: maximum of 23 months in AML cohort and 34 months in MDS cohort
Locations
33 sites in 6 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham the Kirklin Clinic
Birmingham, Alabama
University of Alabama at Birmingham
Birmingham, Alabama
UC San Diego Moores Cancer Center
La Jolla, California
Smilow Cancer Center at Yale New Haven Hospital
New Haven, Connecticut
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Roswell Park Cancer Institute
Buffalo, New York
Stony Brook University Hospital Cancer Center
Stony Brook, New York
Stony Brook University
Stony Brook, New York
Montefiore Einstein Center for Cancer
The Bronx, New York
Montefiore Medical Center
The Bronx, New York
Duke University Health System: Adult Bone Marrow Transplant Clinic
Durham, North Carolina
Duke University Health System, Duke University Hospital
Durham, North Carolina
Duke University Health System
Durham, North Carolina
Investigational Chemotherapy Service
Durham, North Carolina
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio
Henry-Joyce Cancer Center
Nashville, Tennessee
Vanderbilt - Ingram Cancer Center
Nashville, Tennessee
Huntsman Cancer Hospital
Salt Lake City, Utah
Huntsman Cancer Institute
Salt Lake City, Utah
Seattle Cancer Care Alliance (SCCA)
Seattle, Washington
University of Washington Medical Center (UWMC)
Seattle, Washington
Ziekenhuis Netwerk Antwerpen - Campus Stuivenberg
Antwerp, Belgium
UZ Leuven
Leuven, Belgium
Tom Baker Cancer Center
Calgary, Alberta, Canada
University Of Alberta Hospital
Edmonton, Alberta, Canada
CHU d'Amiens-Picardie - Hopital SUD
Amiens, France
Hopital Saint-Louis (AP-HP) - Service Hematologie Senior
Paris, France
Hospices Civils de Lyon - Hopital Lyon Sud- Hematologie
Pierre-Bénite, France
CHU de Tours-Hopital Bretonneau-Centre Regional de cancerologie Henry Kaplan
Tours, France
Staedtisches Klinikum Braunschweig gGmbH
Braunschweig, Germany
King's College Hospital
London, United Kingdom
The Newcastle Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.